Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$183,256 Mln
Revenue (TTM)
$44,328 Mln
Net Profit (TTM)
$6,524 Mln
ROE
0.1 %
ROCE
10 %
P/E Ratio
28.8
P/B Ratio
3.5
Industry P/E
--
EV/EBITDA
15.6
Div. Yield
2.2 %
Debt to Equity
0.3
Book Value
$29.8
EPS
$3.7
Face value
--
Shares outstanding
1,737,674,869
CFO
$63,126.00 Mln
EBITDA
$66,879.00 Mln
Net Profit
$38,861.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
| -15.8 | -6.0 | -15.9 | -17.2 | 2.8 | -2.6 | 10.0 |
|
BSE Sensex
| -12.0 | -9.7 | -12.2 | -1.2 | 8.7 | 8.4 | 11.6 |
|
S&P 100
| -8.0 | -5.1 | -7.0 | 16.0 | 21.2 | 12.4 | 13.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
| 10.8 | 2.7 | 0.3 | -22.0 | 30.5 | 28.0 | 22.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abbott Laboratories (ABT)
|
105.5 | 183,256.0 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 28.8 | 3.5 |
| 154.1 | 55,840.6 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 25.6 | 1.8 | |
| 69.5 | 103,708.8 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 36 | 4.3 | |
| 189.4 | 133,896.8 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.6 | 2.5 | |
| 82.5 | 47,916.0 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.6 | 4.6 | |
| 577.3 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 | |
| 478.0 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 226.0 | 33,194.2 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.5 | 5.2 | |
| 335.7 | 128,457.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40 | 5.7 | |
| 474.4 | 176,228.4 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.7 | 3.3 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and... Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois. Read more
Chairman of the Board, President & CEO
Mr. Robert B. Ford
Chairman of the Board, President & CEO
Mr. Robert B. Ford
Headquarters
Abbott Park, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Abbott Laboratories (ABT) is $105.46 (NYSE) as of 20-Mar-2026 16:19 EDT. Abbott Laboratories (ABT) has given a return of 2.82% in the last 3 years.
The P/E ratio of Abbott Laboratories (ABT) is 28.81 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
33.55
|
4.20
|
|
2024
|
14.74
|
4.14
|
|
2023
|
33.62
|
4.98
|
|
2022
|
27.78
|
5.25
|
|
2021
|
35.47
|
7.01
|
The 52-week high and low of Abbott Laboratories (ABT) are Rs 139.05 and Rs 105.27 as of 21-Mar-2026.
Abbott Laboratories (ABT) has a market capitalisation of $ 183,256 Mln as on 20-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Abbott Laboratories (ABT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.73
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.